Can a phosphate binder curb kidney stone risk?

NCT ID NCT03346369

Completed Disease control Sponsor: Universitair Ziekenhuis Brussel Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial tests whether lanthanum carbonate, a drug typically used to bind phosphate, can also reduce oxalate levels in urine. People with secondary hyperoxaluria and a history of kidney stones take the drug with meals for 28 days, with the dose increasing after two weeks. The goal is to see if this approach safely lowers urinary oxalate, a key driver of stone formation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lanthanum carbonate (Fosrenol), a phosphate binder taken with meals
What this could lead to: If effective, this could offer a new way to lower urine oxalate and potentially reduce kidney stone formation in people with secondary hyperoxaluria.
What could go wrong: This is a short-term, open-label trial with a small number of participants, so results may not be conclusive or generalizable. Possible side effects include gastrointestinal issues and phosphate depletion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEPHROLITHIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hyperoxaluria nephrolithiasis urolithiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEPHROLITHIASIS SECONDARY HYPEROXALURIA

Contacts and locations

Locations

University Hospital Brussels

Brussels, 1090, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.